I am not sure the extent of information that has been shared...

I am not sure the extent of information that has been shared with EMA, specially around latest data on AIPAC, but you would think, even if that data was not "presented" to EMA, they would have been part of scientific consideration in formulating IBM'S questions for EMA, and discussions and the step achieved now. I would doubt if the results were not good, IMM would risk its footing with EMA (&FDA) by just jump the gun. So, another indicationAIPAC data is exciting and/as leading us to phase III, passing the "bottle neck" Ph II, as known in the clinic trial world.

Please also know that fast tracking status is/was a VIP access to EMA/FDA for advice. This may well be some of the benefit already.